Primary Results of the Health-Related Quality of Life Assessment from the Phase III Gadolin Study of Obinutuzumab Plus Bendamustine Compared with Bendamustine Alone in Patients with Rituximab-Refractory, Indolent Non-Hodgkin Lymphoma

被引：0

作者：

Cheson, Bruce D. ^{[1
]}

Trask, Peter C. ^{[2
]}

Gribben, John ^{[3
]}

Dimier, Natalie ^{[4
]}

Kimby, Eva ^{[5
]}

Lugtenburg, Pieternella J. ^{[6
]}

Thieblemont, Catherine ^{[7
]}

Fritsch, Elisabeth Wassner ^{[8
]}

Sehn, Laurie H. ^{[9
,10
]}

机构：

[1] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA

[2] Genentech Inc, San Francisco, CA 94080 USA

[3] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, London, England

[4] F Hoffmann La Roche Ltd, Welwyn Garden City, England

[5] Karolinska Inst, Div Hematol, Dept Med Huddinge, Stockholm, Sweden

[6] Erasmus MC Canc Inst, Rotterdam, Netherlands

[7] Hop St Louis, Paris, France

[8] F Hoffmann La Roche Ltd, Basel, Switzerland

[9] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada

[10] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4